NovoCure Limited

Stocks

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-09 pm EDT			5-day change	1st Jan Change
17.24 ^USD	+2.31%		+8.98%	+33.33%

Jun. 05	Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing	MT
Jun. 05	NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026	CI

Transcript : NovoCure Limited - Special Call

Published on 05/31/2025 at 11:20 pm EDT - Modified on 06/02/2025 at 04:52 pm EDT

S&P Capital IQ

Presenter Speech
William Doyle (Executives)

Hello. Good evening, everyone. Welcome to Chicago, welcome to ASCO, and welcome to Novocure's post-PANOVA-3 investor event. It's my great pleasure to host

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about NovoCure Limited

Jun. 05	Novocure Insider Sold Shares Worth $614,635, According to a Recent SEC Filing	MT
Jun. 05	NovoCure Limited Elects Frank Leonard as Director, Effective June 3, 2026	CI
Apr. 30	NovoCure Limited, Q1 2026 Earnings Call, Apr 30, 2026
Apr. 30	NovoCure Limited Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	NovoCure Shares Rise Following Q1 Financial Results	MT
Apr. 30	(NVCR) NovoCure Expects Full Year 2026 Revenue Range $690M - $710M, vs. FactSet Est of $694.7M	MT
Apr. 30	Earnings Flash (NVCR) NovoCure Posts Q1 Net Loss $0.62 a Share, vs. FactSet Est of $0.51 Loss	MT
Apr. 30	Earnings Flash (NVCR) Novocure Limited Reports Q1 Revenue $174.1M, vs. FactSet Est of $167.8M	MT
Apr. 30	NovoCure Limited Updates Earnings Guidance for the Full Year 2026	CI
Apr. 15	Tango Therapeutics, Inc. Announces Leadership Appointments	CI
Apr. 01	Zymeworks Inc. Announces Executive Changes, Effective from April 1, 2026	CI
Apr. 01	Zymeworks Inc. Announces Chief Financial Officer Changes, Effective April 1, 2026	CI
Mar. 26	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Amid Ongoing Middle East Tensions	MT
Mar. 26	NovoCure Says Phase 2 Trial of TTFields With Atezolizumab Meets Primary Endpoint in Pancreatic Cancer	MT
Mar. 26	Novocure Announces Positive Topline Results From Phase 2 PANOVA-4 Clinical Trial Of Tumor Treating Fields Therapy For Metastatic Pancreatic Cancer	CI